Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Noordijk, E. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Noordijk, E. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 9:S63-S65, 1998
© 1998 European Society for Medical Oncology

Reviews

Radiotherapy in early stage Hodgkin's disease: Principles and results of recent clinical trials

E. M. Noordijk

Department of Clinical Oncology, Division of Radiation Oncology, Leiden University Medical Center Leiden, The Netherlands

Correspondence to: Dr. E. M. Noordijk, Department of Clinical Oncology, Division of Radiation Oncology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands

For decades, radiotherapy has been used as a single treatment modality for early stage Hodgkin's disease. In recent years, late radiation effects, such as myocardial infarctions and induced solid tumours, have become of major concern. It now seems clear that chemotherapy coupled with radiotherapy not only improves relapse-free survival, but can also replace radiotherapy as adjuvant treatment for subclinical disease. This offers the opportunity of reduction of extended fields and high doses, which hopefully correlates with lower late radiation tox-icity. The challenge for clinical trials on the treatment of early stages Hodgkin's disease in the coming years will be the tradeoff between adjuvant radiotherapy and adjuvant chemotherapy, reducing radiotherapy in volume and dose without jeopardising the 90% overall survival that can be achieved nowadays.

chemotherapy, combined modality treatment, early stages, Hodgkin's disease, induced tumours, late toxicity, radiotherapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.